Dishman Carbogen Amcis Limited

DCAL

INE385W01011

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:19:41 11/07/2025 pm IST			5-day change	1st Jan Change
254.85 ^INR	+0.06%		-2.88%	-5.78%

10/07	Dishman Carbogen Amcis Limited, Q4 2025 Earnings Call, May 22, 2025
27/05	Dishman Carbogen Amcis Limited Announces the Demise of Shri Janmejay R. Vyas, Chairman & Non-Executive Director on May 27, 2025	CI

Dishman Carbogen Amcis To Consider And Approve Proposal Of Fund Raising

Published on 07/03/2025 at 17:17

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited, Q4 2025 Earnings Call, May 22, 2025	10/07
Dishman Carbogen Amcis Limited Announces the Demise of Shri Janmejay R. Vyas, Chairman & Non-Executive Director on May 27, 2025	27/05	CI
Dishman Carbogen Amcis Limited Reports Earnings Results for the Full Year Ended March 31, 2025	22/05	CI
Dishman Carbogen Amcis Says Subsidiary Awarded Drug Manufacturing License From Chinese NMPA	21/04	RE
Dishman Carbogen's Shanghai Unit Gets Drug Manufacturing License	10/04	MT
Dishman Carbogen Amcis Says Unit Receives Drug Manufacturing License From NMPA For Shanghai Site	09/04	RE
Dishman Carbogen Amcis Limited Announces Resignations of Independent Directors	01/04	CI
Dishman Carbogen Amcis Raises INR500 Million Through Allotment of Debentures	26/03	MT
Dishman Carbogen Arm Gets French GMP Certification for Saint-Beauzire, France Site	25/03	MT
Dishman Carbogen Amcis Subsidiary Receives GMP Compliance Certificate for France Site	20/03	MT
Dishman Carbogen Amcis's unit Gets GMP Compliance Certificate For Saint-Beauzire Site	19/03	RE
Dishman Carbogen Amcis Gets Board for Up To INR500 Million Debenture Issue	13/03	MT
Dishman Carbogen Amcis Approves Issue Of Debentures Up To 500 Million Rupees	12/03	RE
Dishman Carbogen Amcis To Consider And Approve Proposal Of Fund Raising	07/03	RE
Dishman Carbogen Amcis Turns to Profit in Fiscal Q3	13/02	MT
Dishman Carbogen Amcis Limited, Q3 2025 Earnings Call, Feb 13, 2025	13/02
Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	12/02	CI
Dishman Carbogen Amcis Limited Approves Appointment of Kulin N. Shah as an Independent Director	04/02	CI
Dishman Carbogen Amcis Limited Announces Cessation of Subir Kumar Das as Independent Director, Effective 15 December, 2024	14/12	CI
Dishman Carbogen Amcis Limited, Q2 2025 Earnings Call, Nov 14, 2024	14/11
Dishman Carbogen Amcis Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	13/11	CI
Dishman Carbogen Amcis Limited - Shareholder/Analyst Call	27/24/27
Dishman Carbogen Amcis Limited Auditor Raises 'Going Concern' Doubt	03/24/03	CI
Dishman Carbogen Amcis Limited, Q1 2025 Earnings Call, Aug 14, 2024	14/24/14
Dishman Carbogen Amcis Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	13/24/13	CI

Chart Dishman Carbogen Amcis Limited

Duration

Period

DCAL: Dynamic Chart

Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.

Employees

1,132

Sector

Pharmaceuticals

Calendar

06/08 - Q1 2026 Earnings Release (Projected)

More about the company